Product Code: 02-LUNGT-26
From £299.00 Early Bird
Early Bird Deadline: 31/01/2026
Deadline to order: 28/02/2026
This EQA has two modules: COMMON BIOMARKERS (mandatory to participate in this EQA) and NEW & EMERGING BIOMARKERS (optional to participate in this EQA) both using FFPE to test.
If you are planning to participate in the Lung cancer (NSCLC) [Tissue] EQA scheme, it is MANDATORY to participate in the COMMON BIOMARKERS module which is designed to assess performance and reporting in routine Lung cancer tissue testing using commonly tested biomarkers in the EGFR, KRAS and BRAF genes. If you are undertaking extended testing using new or emerging biomarkers in your clinical service, then you can also select the option to register for the OPTIONAL NEW and EMERGING BIOMARKERS module; the genes we include vary year on year, and may include, for example, variants in the EGFR, ERBB2, KRAS, TP53 and MET genes.
NGS, Panel testing, PCR based, Whole exome sequencing, Whole genome sequencing
English, French, German, Italian, Spanish
FFPE
Yes
June 2026
June - August 2026
December 2026 - January 2027
You can complete purchase on our secure partner site.
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
Mock clinical cases with matching human tumour tissue paraffin embedded (FFPE) and/or artificial FFPE reference materials (designed to simulate real patient samples) are provided for both the COMMON BIOMARKERS module and the NEW & EMERGING BIOMARKERS module. Five cases are provided for each EQA module. One 10um or 15um thick FFPE section per case is provided.
Variant allele frequencies of any artificial FFPE materials have been validated using ddPCR.
There is a maximum of 2 x additional sets of samples per participant for COMMON BIOMARKERS and 3 x additional sets of samples per participant for NEW & EMERGING BIOMARKERS.
Participants will receive an individual report including educational advice and a scheme summary report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics which allow participants to benchmark their results.
For the COMMON BIOMARKERS EQA option, the minimum requirement is EGFR, KRAS and BRAF gene testing. For EGFR testing, laboratories can expect variants in all four Tyrosine Kinase (TK) domain exons.
For the NEW & EMERGING BIOMARKERS EQA option, the testing requirements will be detailed in the Scheme Instructions.
These samples are not suitable for an RNA-based methodology only.
Participants are expected to test samples according to their routine strategy. Submission of a .pdf clinical report is required for one case of each EQA module. The remaining cases require genotyping only. For all cases, mandatory completion of an online data collection form is also required.
This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. The EQA providers acknowledge and thank AstraZeneca for this support.
Limited to a maximum of 400 participants, please register early to make sure you don’t miss out. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
